Subtopic Deep Dive
Glucose-6-Phosphatase Deficiency
Research Guide
What is Glucose-6-Phosphatase Deficiency?
Glucose-6-phosphatase deficiency is an autosomal recessive disorder classified as glycogen storage disease type I (GSD-I), primarily GSD-Ia due to mutations in the G6PC gene, causing impaired hepatic glucose production and severe hypoglycemia.
GSD-Ia results from deficiency of the membrane-bound enzyme glucose-6-phosphatase, essential for the final step in gluconeogenesis and glycogenolysis (Van Schaftingen and Gerin, 2002, 384 citations). Incidence is 1 in 100,000 with subtypes GSD-Ia and GSD-Ib (Chou et al., 2002, 293 citations). Over 50 papers detail its pathophysiology, management, and genetic mutations.
Why It Matters
GSD-I management guidelines by Kishnani et al. (2014, 472 citations) standardize diagnosis and therapy, reducing metabolic crises through cornstarch and continuous glucose monitoring. Chou et al. (2008, 183 citations) identified G6PC mutations enabling genetic diagnosis and potential gene therapy. Froissart et al. (2011, 240 citations) highlight risks of kidney/liver tumors, guiding long-term surveillance and interventions that improve survival from infancy to adulthood.
Key Research Challenges
Hypoglycemia Management
Frequent metabolic crises from impaired glucose release persist despite therapies (Kishnani et al., 2014). Continuous glucose monitoring optimizes uncooked cornstarch dosing but requires nighttime interventions. Long-term compliance remains difficult in pediatric patients.
Hepatorenal Tumor Risk
GSD-Ia patients develop adenomas and hepatocellular carcinoma due to glycogen overload (Froissart et al., 2011). Surveillance protocols exist but early detection methods lag. Balancing immunosuppression with tumor prevention challenges therapy.
Gene Therapy Development
G6PC mutations vary widely, complicating AAV-based delivery (Chou and Mansfield, 2008). Chaperone molecules show promise but lack clinical trials. Translating animal models to humans faces immune response hurdles.
Essential Papers
Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics
Priya S. Kishnani, Stephanie Austin, José E. Abdenur et al. · 2014 · Genetics in Medicine · 472 citations
Specific features of glycogen metabolism in the liver
Mathieu Bollen, Stefaan Keppens, Willy Stalmans · 1998 · Biochemical Journal · 393 citations
Although the general pathways of glycogen synthesis and glycogenolysis are identical in all tissues, the enzymes involved are uniquely adapted to the specific role of glycogen in different cell typ...
The glucose-6-phosphatase system
Emile Van Schaftingen, Isabelle Gerin · 2002 · Biochemical Journal · 384 citations
Glucose-6-phosphatase (G6Pase), an enzyme found mainly in the liver and the kidneys, plays the important role of providing glucose during starvation. Unlike most phosphatases acting on water-solubl...
Type I Glycogen Storage Diseases: Disorders of the Glucose-6- Phosphatase Complex
Janice Y. Chou, Dietrich Matern, Brian C. Mansfield et al. · 2002 · Current Molecular Medicine · 293 citations
Glycogen storage disease type I (GSD-I) is a group of autosomal recessive disorders with an incidence of 1 in 100,000. The two major subtypes are GSD-Ia (MIM232200), caused by a deficiency of gluco...
Glycogen metabolism has a key role in the cancer microenvironment and provides new targets for cancer therapy
Christos E. Zois, Adrian L. Harris · 2016 · Journal of Molecular Medicine · 248 citations
Metabolic reprogramming is a hallmark of cancer cells and contributes to their adaption within the tumour microenvironment and resistance to anticancer therapies. Recently, glycogen metabolism has ...
Glucose-6-phosphatase deficiency
Roseline Froissart, Monique Piraud, Alix Mollet Boudjemline et al. · 2011 · Orphanet Journal of Rare Diseases · 240 citations
Glycogen storage disease type I and G6Pase-β deficiency: etiology and therapy
Janice Y. Chou, Hyun Sik Jun, Brian C. Mansfield · 2010 · Nature Reviews Endocrinology · 234 citations
Reading Guide
Foundational Papers
Start with Kishnani et al. (2014, 472 citations) for clinical guidelines; Van Schaftingen and Gerin (2002, 384 citations) for G6Pase mechanics; Chou et al. (2002, 293 citations) for disease subtypes and genetics.
Recent Advances
Chou et al. (2010, 234 citations) on etiology/therapy; Froissart et al. (2011, 240 citations) on deficiency features; Chou and Mansfield (2008, 183 citations) on mutations.
Core Methods
Enzyme assays, G6PC sequencing, continuous glucose monitoring, uncooked cornstarch dosing, AAV gene therapy vectors.
How PapersFlow Helps You Research Glucose-6-Phosphatase Deficiency
Discover & Search
Research Agent uses searchPapers for 'GSD-Ia glucose-6-phosphatase mutations' yielding Kishnani et al. (2014, 472 citations); citationGraph maps forward citations to recent therapy trials; findSimilarPapers expands to Chou et al. (2002); exaSearch uncovers niche uncooked cornstarch studies.
Analyze & Verify
Analysis Agent applies readPaperContent to extract mutation data from Chou et al. (2008); verifyResponse with CoVe cross-checks prevalence claims against Froissart et al. (2011); runPythonAnalysis simulates glucose homeostasis models using NumPy/pandas on G6Pase kinetics from Van Schaftingen (2002); GRADE grading scores guideline strength in Kishnani et al. (2014).
Synthesize & Write
Synthesis Agent detects gaps in gene therapy trials post-Chou et al. (2010); flags contradictions between tumor risks in Froissart (2011) and metabolism reviews; Writing Agent uses latexEditText for case reports, latexSyncCitations for 20+ refs, latexCompile for review PDFs, exportMermaid for G6Pase pathway diagrams.
Use Cases
"Model GSD-Ia hypoglycemia risk with patient glucose data"
Research Agent → searchPapers (Kishnani 2014) → Analysis Agent → runPythonAnalysis (pandas simulation of cornstarch dosing → matplotlib risk curves) → researcher gets downloadable CSV of personalized therapy thresholds.
"Draft GSD-I management review with citations and figures"
Synthesis Agent → gap detection (therapy updates post-2014) → Writing Agent → latexEditText (add sections) → latexSyncCitations (Kishnani/Chou refs) → latexCompile → researcher gets compiled PDF with G6Pase diagram.
"Find code for glucose-6-phosphatase enzyme simulations"
Research Agent → paperExtractUrls (metabolism papers) → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets runnable Python scripts modeling G6Pase deficiency kinetics.
Automated Workflows
Deep Research workflow scans 50+ GSD-I papers via citationGraph from Kishnani (2014), producing structured reports on subtype differences. DeepScan's 7-step chain verifies mutation impacts in Chou (2008) with CoVe checkpoints and Python glucose modeling. Theorizer generates hypotheses on chaperone therapies from Van Schaftingen (2002) enzyme mechanisms.
Frequently Asked Questions
What defines glucose-6-phosphatase deficiency?
It is GSD-Ia, caused by G6PC gene mutations preventing glucose-6-phosphate hydrolysis in liver/kidney, leading to hypoglycemia and lactic acidosis (Chou et al., 2002).
What are main diagnostic methods?
Genetic testing for G6PC mutations and liver biopsy for enzyme activity; guidelines in Kishnani et al. (2014) recommend newborn screening where available.
What are key papers?
Kishnani et al. (2014, 472 citations) for management; Van Schaftingen and Gerin (2002, 384 citations) for G6Pase system; Chou et al. (2002, 293 citations) for subtypes.
What open problems exist?
No curative therapy; gene therapy trials pending, tumor prevention suboptimal, long-term uncooked cornstarch adherence poor (Froissart et al., 2011; Chou et al., 2010).
Research Glycogen Storage Diseases and Myoclonus with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Glucose-6-Phosphatase Deficiency with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers